The dysregulation of these oncogenes drives B-cell hematological malignancies such as follicular lymphoma (BCL2 translocation, MLL2 inactivation) (11, 67) DLBCL (e.g. BCL6, BCL2 and MYC translocation) (8, 68, 69) or Burkitt’s lymphoma (MYC translocation) (70, 71). This evidence concerns the gene BCL6 and follicular lymphoma.